1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
The nasal mucosa offers an effective target for inhaled drugs that either treat localized nasal conditions or quickly deliver drugs to the systemic circulation [1–3]. While nasal spray drug product designs can vary considerably between innovators, most sprays are formulated as either a homogeneous solution or a heterogeneous suspension; in the latter case, solid drug particles are dispersed within a carrier liquid [4]. Despite the many advancements in nasal drug delivery, effectively administering drugs via this route still poses many challenges. One of the main challenges relates to mucociliary motion, which tends to transport and clear drug particles from the nasal cavity after deposition, limiting the available time for drug absorption at the intended site of action [5-8].Many previous nasal spray models have considered solution formulations, where the active drug is already dissolved into a carrier liquid [9-11]. These computational fluid dynamics (CFD) models of nasal spray transport are currently well-developed and show good agreement with in vitro depositional data, but stop at the point of droplet deposition [12-19]. When considering a suspension-type formulation, an accurate model requires simulations of spray droplet transport along with the dissolution of the suspended drug particles in the nasal mucus, during which time mucociliary clearance is occurring. In cases where inhaled particles are either very large or insoluble in mucus, insufficient dissolution may result in reduced drug delivery to the nasal epithelium, reducing the overall effectiveness of the drug product [1,2,20,21]. A recently developed model demonstrates the effects of mucociliary clearance on drug absorption from a suspension formulation [22]. However, this model only considered a flattened surface representation of the nasal cavity, and was therefore unable to show uptake in specific nasal regions (e.g., the olfactory region). To study targeted nasal therapies, it is desirable to model drug uptake in an anatomically-realistic, three-dimensional model.Finally, the effects of interindividual variability on nasal drug delivery and clearance have not been fully quantified. Studies have shown that differences in individual nasal geometry can have a large impact on airflow patterns [26], but the full extent of mucus properties, impaired mucociliary function, or general inflammatory disease states on drug delivery have not been completely explored. Because many nasal spray drug products are used to treat medical conditions that cause variations from a "healthy" state, it is important to quantify how these various factors may influence the overall efficacy of nasal sprays.ObjectivesThe objective is to study the three-dimensional effects of mucociliary clearance on localized drug absorption in respiratory airways, particularly the nasal cavity, utilizing a computational modeling approach. The model should be adaptable to cases of intersubject variability, which may include variations in mucociliary clearance rates, changes in nasal geometry, and the presence of relevant disease states (e.g., nasal inflammation, changes in mucus properties, etc.). The desired outcome is a computational methodology that predicts regional absorption of inhaled drugs, particularly those whose formulations include solid or suspended drug particles and may target specific nasal regions.Detailed DescriptionA computational modeling approach will be developed to study the effects of nasal mucociliary clearance on inhaled drug absorption and the changes that result from differences in drug formulation, disease states, and interindividual anatomical differences. The model should consider realistic three-dimensional nasal airway geometries and account for device effects, inhalation, particle/droplet deposition, and, importantly, drug dissolution and absorption at the epithelium. The approach should provide a direct interface between the mucociliary clearance model and CFD simulations of spray deposition.The physiological model should consider the entire nasal airway from the nostril to the throat; variations to the geometry, representative of interindividual differences, should also be considered. The mucociliary clearance model should be general enough to allow for changes in mucus properties and clearance rates based on healthy and disease states.A straight-forward approach would utilize CFD simulations of inhalation and spray/particle transport to provide regional deposition data, while the three-dimensional mucociliary clearance model would demonstrate localized drug absorption and indicate the efficacy of drug products that target specific nasal regions. Since the development of the methodology for creating the three-dimensional CFD mucociliary clearance model is considered a primary outcome of this research, it is expected that the methodology would be made available to the FDA and preferably to the public as well in such a way that it may be reproduced, either through detailed publication of the methodology and/or through sharing of codes, models, etc. Validation of the CFD simulations with in vitro or in vivo data should be included, which should demonstrate similarity between predicted local mucociliary clearance and in vivo clearance of drug particles. If possible, it is preferable that the model be validated against multiple drug products. All relevant physics should be considered in the model; these physics may include (but are not limited to) spray turbulence, Lagrangian droplet/particle transport, mucus properties, mucociliary clearance, particle dissolution, and drug partitioning between the mucus and nasal epithelium. The proposal can include specific drug products to be studied; however, after award, the selection of drug products will be revisited in a collaborative discussion with the FDA. Suspension formulations or insufflation studies would be encouraged.The study should consist of four phases:Phase 1: Selection, identification, and construction of physiological models and inhalation patterns that will best characterize interindividual variability.Phase 2: Development and validation of the computational fluid dynamics model and mucociliary clearance model.Phase 3: Performance of simulations and post-processing of simulation data.Phase 4: Overall assessment of the relationship between drug product formulation, mucociliary clearance, interindividual variability, and regional drug absorption.Phase 5: Preparation of manuscripts, which is intended to be done in the third year of the grant, and is the reason for the reduced budget for that year. This phase may also begin earlier than the third year.References[1] HR Costantino, L Illum, G Brandt, PH Johnson, and SC Quay: Intranasal delivery: Physicochemical and therapeutic aspects. Intl J Pharma. 2007;337:1–24.[2] AA Hussain: Intranasal drug delivery. Adv Drug Deliv Rev. 1998;29:39–49.[3] S Turker, E Onur, and Y Ozer: Nasal route and drug delivery systems. Pharma World Sci. 2004;26:137–142.[4] SA Shah, RL Berger, J McDermott, P Gupta, D Monteith, A Connor, and W Lin: Regional deposition of mometasone furoate nasal spray suspension in humans. Allergy Asthma Proc. 2015;36:48–57.[5] FA Fry, and A Black: Regional deposition and clearance of particles in the human nose. J Aerosol Sci. 1973;4:113–124.[6] DF Proctor, and G Lundqvist: Clearance of inhaled particles from the human nose. Arch Int Med. 1973;131:132–139.[7] NGM Schipper, JC Verhoef, and FWHM Merkus: The nasal mucociliary clearance: Relevance to nasal drug delivery. Pharm Res. 1991;8:807–814.[8] AG Beule: Physiology and pathophysiology of the paranasal sinuses. GMS Curr Topics Otorhinolaryngol Head Neck Surg. 2010;9.[9] JD Suman, BL Laube, and R Dalby: Comparison of nasal deposition and clearance of aerosol generated by a nebulizer and an aqueous spray pump. Pharma Res. 1999;16:1648–1652.[10] J Hardy, S Lee, and C Wilson: Intranasal drug delivery by spray and drops. J Pharmacy Pharmacol. 1985;37:294–297.[11] PG Djupesland, A Skretting, M Winderen, and T Holand: Breath actuated device improves delivery to target sites beyond the nasal valve. Laryngoscope. 2006;116:466–472.[12] Y Liu, EA Matida, and MR Johnson: Experimental measurements and computational modeling of aerosol deposition in the Carleton-Civic standardized human nasal cavity. J Aerosol Sci. 2010;41:569–586.[13] K Inthavong, Q Ge, CMK Se, W Yang, and JY Tu: Simulation of sprayed particle feposition in a human nasal cavity including a nasal spray device. J Aerosol Sci. 2011;42:100–113.[14] JD Schroeter, JS Kimbell, and B Asgharian: Analysis of particle deposition in the turbinate and olfactory regions using a human nasal computational fluid dynamics model. J Aerosol Med. 2006;19:301–313.[15] H Shi, C Kleinstreuer, and Z Zhang: Modeling of inertial particle transport and deposition in human nasal cavities with wall roughness. J Aerosol Sci. 2007;38:398–419.[16] JD Schroeter, GJM Garcia, and JS Kimbell: Effects of surface smoothness on inertial particle deposition in human nasal models. J Aerosol Sci. 2011;42:52–63.[17] J Xi, X Si, JW Kim, and A Berlinski: Simulation of airflow and aerosol deposition in the nasal cavity of a 5-year-old child. J Aerosol Sci. 2011;42:156–173.[18] SM Wang, K Inthavong, J Wen, JY Tu, and CL Xue: Comparison of micron- and nanoparticle deposition patterns in a realistic human nasal cavity. Resp Physiol Neurobiol. 2009;166:142–151.[19] JS Kimbell, RA Segal, B Asgharian, BA Wong, JD Schroeter, JP Southall, CJ Dickens, G Brace, and FJ Miller: Characterization of deposition from nasal spray devices using a computational fluid dynamics model of the human nasal passages. J Aerosol Med. 2007;20:59–74.[20] P Arora, S Sharma, and S Garg: Permeability issues in nasal drug delivery. Drug Discov Today. 2002;7:967–975.[21] L Illum: Nasal drug delivery: New developments and strategies. Drug Discov Today. 2002;7:1184–1189.[22] Rygg Alex and Longest P. Worth: Absorption and Clearance of Pharmaceutical Aerosols in the Human Nose: Development of a CFD Model. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2016;29(5):416-431.[26] Zhao, Kai and Scherer, Peter W and Hajiloo, Shoreh A and Dalton, Pamela. Effect of Anatomy on Human Nasal Air Flow and Odorant Transport Patterns: Implications for Olfaction. Chemical Senses. 2004;29(5):365-379.
Funding Opportunity Number: RFA-FD-18-020. Assistance Listing: 93.103. Funding Instrument: CA. Category: AG,CP,FN. Award Amount: Up to $280K per award.
Get alerted about grants like this
Save a search for “Food and Drug Administration” or related topics and get emailed when new opportunities appear.
Search similar grants →Based on current listing details, eligibility includes: Eligible applicants: State governments; County governments; City or township governments; Special district governments; Independent school districts; Public and State controlled institutions of higher education; Native American tribal governments (Federally recognized); Public housing authorities / Indian housing authorities; Native American tribal organizations (other than Federally recognized); Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; For-profit organizations other than small businesses; Small businesses. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Up to $280K per award Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is June 4, 2018. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
Past winners and funding trends for this program
The Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Office of Medical Policy (OMP) is announcing its intent to accept and consider a single source application for the award of a grant to the Duke Universitys Duke Translational Medicine Institute (DTMI) to support increasing the quality and efficiency of clinical trials. Funding Opportunity Number: RFA-FD-14-017. Assistance Listing: 93.103. Funding Instrument: G. Category: FN,HL. Award Amount: Up to $7.5M per award.
The Center for Drug Evaluation and Research (CDER) receives a vast and growing amount of data in a variety of regulatory submissions from a multitude of sources and in a variety of formats. This wealth of data holds great potential to advance CDER’s regulatory and scientific work, but the present lack of standardized data creates significant challenges to realizing that potential.The volume and complexity of drug-related information submitted to CDER for regulatory review is creating significant challenges to the Center’s ability to efficiently and effectively perform its critical public health mission.The lack of standardized data affects CDER’s review processes by curtailing a reviewer’s ability to perform integral tasks such as rapid acquisition, analysis, storage and reporting of regulatory data. Improved data quality, accessibility and predictability will give reviewers more time to carry out complex analyses, ask in-depth questions and address late-emerging issues. Standardized data will allow reviewers to increase review consistency and perform evaluations across the drug lifecycle. This will enhance the Center’s performance across key drug regulatory functions and ongoing business operations, including pre-market review, post-market safety, oversight of drug quality, and oversight of drug promotion.In accordance with the Office of Management and Budget (OMB) Circular A-119, the FDA will: use voluntary, consensus-based standards development processes in place of government unique standards unless such standards are inconsistent with law or otherwise impractical; advocate to align these standards with existing health information technology initiatives, laws, regulations, and mandates; and promote coordination with other standards currently in use. The projects selected under this funding opportunity must adhere to these principles. Funding Opportunity Number: RFA-FD-15-033. Assistance Listing: 93.103. Funding Instrument: CA. Category: FN,IS. Award Amount: $50K – $225K per award.
The Food and Drug Administration (FDA), Center for Food Safety and Applied Nutrition (CFSAN), Office of Food Safety (OFS) is announcing its intent to award a single source cooperative agreement to the Interstate Shellfish Sanitation Conference (ISSC). The purpose of this cooperative agreement is to enhance the FDA’s molluscan shellfish sanitation program and provide the public greater assurance of the quality and safety of these products. Molluscan shellfish have been recognized by FDA as a significant source of seafood-borne illnesses and continue to be the subject of congressional, state, industry, and public concern. FDA has given high priority to enhance the agency's shellfish safety program and to provide the public greater assurance of the quality and safety of these products. FDA administers the National Shellfish Sanitation Program (NSSP). Under that program, the NSSP Model Ordinance serves as guidance for State shellfish sanitation programs and the promulgation of state regulations and laws concerning shellfish safety. This cooperative agreement will enhance FDA efforts to help ensure that shellfish are free of harmful pathogens. Funding Opportunity Number: RFA-FD-16-006. Assistance Listing: 93.103. Funding Instrument: CA. Category: AG,CP,FN. Award Amount: Up to $500K per award.